Home LiteratureArticle Details
PMID: 15564511 Published · ppublish English Journal Article

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

Journal of virology ·Vol. 78 ·No. 24 ·2004-12-00 ·Pages 14039-42

Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M

Abstract

As the AIDS epidemic continues unabated, the development of a human immunodeficiency virus (HIV) vaccine is critical. Ideally, an effective vaccine should elicit cell-mediated and neutralizing humoral immune responses. We have determined the in vitro susceptibility profile of sexually transmitted viruses from 91 patients with acute and early HIV-1 infection to three monoclonal antibodies, 2G12, 2F5, and 4E10. Using a recombinant virus assay to measure neutralization, we found all transmitted viruses were neutralized by 4E10, 80% were neutralized by 2F5, and only 37% were neutralized by 2G12. We propose that the induction of 4E10-like antibodies should be a priority in designing immunogens to prevent HIV-1 infection.

MeSH Terms
Antibodies, Monoclonal/administration & dosage,immunology Female HIV Antibodies/administration & dosage,immunology HIV Infections/prevention & control,transmission,virology HIV-1/genetics,immunology Humans Male Neutralization Tests Recombination, Genetic Sexual Behavior
Chemicals
Antibodies, Monoclonal HIV Antibodies
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Mehandru Saurabh
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave., 7th Floor, New York, NY 10016, USA.
Wrin Terri
Galovich Justin
Stiegler Gabriela
Vcelar Brigitta
Hurley Arlene
Hogan Christine
Vasan Sandhya
Katinger Hermann
Petropoulos Christos J
Markowitz Martin
References (25)
25 references, click to expand
  1. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
  2. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  3. Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge.
    Virology. 2000 Dec 20;278(2):551-61 PMID: 11118377
  4. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
    J Virol. 2001 Aug;75(16):7470-80 PMID: 11462019
  5. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    J Virol. 2001 Nov;75(22):10892-905 PMID: 11602729
  6. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65 PMID: 11788027
  7. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.
    AIDS. 2002 Jan 25;16(2):227-33 PMID: 11807307
  8. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.
    AIDS. 2002 Oct 18;16(15):2019-25 PMID: 12370500
  9. Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.
    Vaccine. 2002 Dec 19;20 Suppl 4:A61-5 PMID: 12477430
  10. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques.
    AIDS. 2003 Feb 14;17(3):301-9 PMID: 12556683
  11. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
    J Virol. 2003 Apr;77(8):5037-8 PMID: 12663814
  12. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Science. 2003 Jun 27;300(5628):2065-71 PMID: 12829775
  13. HIV vaccine design and the neutralizing antibody problem.
    Nat Immunol. 2004 Mar;5(3):233-6 PMID: 14985706
  14. Prospects for an AIDS vaccine.
    Nat Med. 2004 Mar;10(3):221-3 PMID: 14991035
  15. Genetic immunization is a simple method for eliciting an immune response.
    Nature. 1992 Mar 12;356(6365):152-4 PMID: 1545867
  16. Gene inoculation generates immune responses against human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156-60 PMID: 8483929
  17. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  18. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    J Infect Dis. 1996 Feb;173(2):340-8 PMID: 8568294
  19. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate.
    J Virol. 1996 Oct;70(10):6751-8 PMID: 8794312
  20. Neutralization of HIV-1 by antibody.
    Curr Opin Immunol. 1996 Aug;8(4):540-5 PMID: 8794008
  21. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.
    J Virol. 1998 Feb;72(2):1403-10 PMID: 9445041
  22. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  23. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.
    JAMA. 1998 Jul 1;280(1):42-8 PMID: 9660362
  24. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    J Infect Dis. 1999 Mar;179(3):527-37 PMID: 9952358
  25. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.
    Antimicrob Agents Chemother. 2000 Apr;44(4):920-8 PMID: 10722492
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.78.24.14039-14042.2004
Published
2004-12-00
Pages
14039-42
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC533925
Subset
IM
External Links
PubMed source DOI: 10.1128/JVI.78.24.14039-14042.2004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2